title: Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome.
abstract: OBJECTIVE
  We report a case of autoimmune lymphoproliferative syndrome (ALPS) presenting with bilateral uveitis.
  
  
  METHODS
  Observational case report.
  
  
  METHODS
  Review of case record, serum and aqueous IL-10 and IL-6 cytokine results, and immunosuppressive treatment of a patient with a mutation in the gene encoding Fas.
  
  
  RESULTS
  Control of the intermediate uveitis required sustained doses of topical and periocular corticosteroids as well as systemic cyclosporine. The serum IL-10 level was elevated, as commonly seen in ALPS, but the aqueous IL-10 was not.
  
  
  CONCLUSIONS
  Despite a Th2 immune predominance in ALPS, uveitis, a Th1-mediated disease, may still manifest in these patients. The pathogenesis of uveitis in ALPS may differ from that of the systemic disease overall. Long-term follow-up is required for patients with uveitis associated with ALPS.
authors.affiliation: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-1857, USA.
authors.forename: Wee-Kiak
authors.initials: WK
authors.lastname: Lim
authors.forename: Roxana
authors.initials: R
authors.lastname: Ursea
authors.forename: Koneti
authors.initials: K
authors.lastname: Rao
authors.forename: Ronald R
authors.initials: RR
authors.lastname: Buggage
authors.forename: Eric B
authors.initials: EB
authors.lastname: Suhler
authors.forename: Faith
authors.initials: F
authors.lastname: Dugan
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Straus
authors.forename: Robert B
authors.initials: RB
authors.lastname: Nussenblatt
mesh_terms: D001082:Aqueous Humor / Q000378:metabolism; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D009154:Mutation; D018417:Th1 Cells / Q000276:immunology; D015867:Uveitis, Intermediate / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D019014:fas Receptor / Q000235:genetics
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D019014:fas Receptor; D016753:Interleukin-10